| Literature DB >> 35884120 |
Kuan-Jen Chen1,2, Yen-Po Chen1,2,3, Yi-Hsing Chen1,2, Laura Liu1,2, Nan-Kai Wang4, An-Ning Chao1,2, Wei-Chi Wu1,2, Yih-Shiou Hwang1,2, Hung-Da Chou1,2, Eugene Yu-Chuan Kang1,2, Yen-Ting Chen1, Ming-Hui Sun1,2, Chi-Chun Lai1,2,5.
Abstract
Endogenous endophthalmitis is an uncommon intraocular infection with potentially devastating consequences on vision. Klebsiella pneumoniae is highly prevalent in East Asian countries, with an increasing incidence recently worldwide. This retrospective study investigates infection sources and antibiotic susceptibilities of K. pneumoniae in patients with endogenous K. pneumoniae endophthalmitis (EKE) in Northern Taiwan. One hundred and fifty-seven patients with EKE were reviewed between January 1996 and April 2019. Pyogenic liver abscess (120/157, 76.4%) was the most common infection source, followed by pneumonia (13, 8.3%), urinary tract infection (7, 4.5%), and intravenous drug use (4, 2.5%). Bilateral involvement was identified in 12.1% (19/157) of patients, especially in patients with pyogenic liver abscess (16/120, 13.3%), pneumonia (2/13, 15.4%), and urinary tract infection (1/7, 14.3%). The antibiotic susceptibility rates were 98.1%, 92.5%, 97.5%, 96.8%, 100%, 99.3%, and 100% for amikacin, cefuroxime, ceftazidime, ceftriaxone, carbapenems, ciprofloxacin, and levofloxacin, respectively. Four extended-spectrum β-lactamase-producing multidrug-resistant (MDR) K. pneumoniae isolates were identified. In conclusion, pyogenic liver abscess was the major infection source in EKE. In addition, K. pneumoniae was still highly susceptible to ceftazidime and amikacin, and the MDR K. pneumoniae isolates were not common in EKE.Entities:
Keywords: Klebsiella pneumoniae; antibiotic susceptibility; endogenous endophthalmitis; liver abscess
Year: 2022 PMID: 35884120 PMCID: PMC9311537 DOI: 10.3390/antibiotics11070866
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Infection sources of endogenous Klebsiella pneumoniae endophthalmitis.
| Infectious Source | No. of Patients | Percent | Bilateral | Percent |
|---|---|---|---|---|
| Pyogenic liver abscess *† | 120 | 76.4% | 16 | 13.3% |
| Pneumonia ‡ | 13 | 8.3% | 2 | 15.4% |
| Urinary tract infection/renal abscess | 7 | 4.5% | 1 | 14.3% |
| Intravenous drug user | 4 | 2.5% | ||
| Necrotizing fasciitis | 1 | 0.6% | ||
| Cellulitis | 1 | 0.6% | ||
| Brain abscess | 1 | 0.6% | ||
| Neck abscess | 1 | 0.6% | ||
| Spleen abscess | 1 | 0.6% | ||
| Retroperitoneal nonorganic abscess | 1 | 0.6% | ||
| Rectal perforation with sepsis | 1 | 0.6% | ||
| Peritonitis | 1 | 0.6% | ||
| Colon cancer with necrosis | 1 | 0.6% | ||
| Not identified | 4 | 2.5% | ||
| Total | 157 | 100% | 19 | 12.1% |
* Three patients with hepatobiliary tract infection but no obvious liver abscess on abdominal echography or computed tomography. † Five patients with meningitis, 20 patients with pneumonia, and one patient with prostate abscess. ‡ Primary infection with pneumonia was not associated with pyogenic liver abscess.
Distribution of Klebsiella pneumoniae isolated from different samples.
| Sample | No. of Patients | % |
|---|---|---|
| Blood | 124 | 79.0 |
| Eye | 65 | 41.4 |
| Abscesses | 58 | 36.9 |
| Urine | 30 | 19.1 |
| Sputum | 13 | 8.3 |
| Wound swab | 3 | 1.9 |
| Plural effusion | 3 | 1.9 |
| Endotracheal aspirates | 2 | 1.3 |
| Ascites | 1 | 0.6 |
| Total | 157 | 100 |
Antibiotic susceptibility of Klebsiella pneumoniae.
| Antibiotics | Tested | Sensitive | Intermediate | Resistant | |
|---|---|---|---|---|---|
| Interval | No. (%) | No. (%) | No. (%) | Diseases (Number) | |
| Ampicillin | 1996–2006 | 75/75 (100%) | All diseases | ||
| Ampicillin-sulbactam | 2007–2010 | 44/46 (95.7%) | 2/46 (4.3%) | Liver abscess (2) | |
| Amoxicillin-clavulanate | 2010–2019 | 22/22 (100%) | |||
| Ticarcillin | 1996–1997 | 4/4 (100%) | Liver abscess (4) | ||
| Piperacillin | 1996–2010 | 75/93 (81.7%) | 5/93 (5.4%) | 13/93 (14.0%) | Liver abscess (9), pneumonia (4) |
| Piperacillin-tazobactam | 2007–2019 | 64/67 (95.5%) | 2/67 (3.1%) | 1/67 (1.5%) | Liver abscess (1) |
| Gentamicin | 1996–2019 | 153/157 (97.5%) | 4/157 (2.5%) | Pneumonia (2), spleen abscess (1), IVDU (1), | |
| Amikacin | 1996–2019 | 154/157 (98.1%) | 3/157 (1.9%) | Pneumonia (2), spleen abscess (1) | |
| Sulfamethoxazole-trimethoprim | 1996–2010 | 91/96 (95.8%) | 5/96 (4.2%) | Pneumonia (2), liver abscess (2),spleen abscess (1) | |
| Cephalothin | 1996–2000 | 20/20 (100%) | |||
| Cefazolin | 1996–2009 | 82/89 (92.1%) | 7/89 (7.9%) | Liver abscess (3), pneumonia (2), spleen abscess (1), IVDU (1), | |
| Cefuroxime | 1999–2019 | 135/146 (92.5%) | 11/146 (7.5%) | Liver abscess (7), pneumonia (2), spleen abscess (1), IVDU (1) | |
| Ceftriaxone | 1996–2019 | 152/157 (96.8%) | 5/157 (3.2%) | Pneumonia (2), spleen abscess (1), IVDU (1), liver abscess (1) | |
| Ceftazidime | 1996–2019 | 153/157 (97.5%) | 4/157 (2.6%) | Pneumonia (2), spleen abscess (1), IVDU (1), | |
| Flomoxef | 2007–2012 | 18/20 (90%) | 2/20 (10%) | Pneumonia (2) | |
| Cefepime | 2008–2013 | 16/16 (100%) | |||
| Cefoperazone-sulbactam | 2016–2019 | 10/10 (100%) | |||
| Aztreonam | 1999–2009 | 90/95 (94.7%) | 5 (5.3%) | Pneumonia (2), spleen abscess (1), IVDU (1), liver abscess (1) | |
| Imipenem | 1996–2006 | 82/82 (100%) | |||
| Ertapenem | 2007–2019 | 71/71 (100%) | |||
| Meropenem | 2007 | 1/1 (100%) | |||
| Ciprofloxacin | 2000–2009 | 130/131 (99.3%) | 1/131 (0.7%) | Pneumonia (1) | |
| Levofloxacin | 2010–2019 | 65/65 (100%) | |||
IVDU, intravenous drug use.
Antibiotic susceptibility testing in multidrug-resistant Klebsiella pneumoniae.
| Antibiotics |
| |||
|---|---|---|---|---|
| No. of | 1 | 2 | 3 | 4 |
| Infection Source | Pneumonia | Pneumonia | Spleen | IVDU |
| Ampicillin | R | R | R | |
| Amoxicillin-clavulanic acid | S | |||
| Piperacillin | R | R | S | R |
| Piperacillin-tazobactam | S | S | ||
| Gentamicin | R | R | R | R |
| Amikacin | R | R | R | S |
| Cefazolin | R | R | R | R |
| Cefuroxime | R | R | R | R |
| Ceftriaxone | R | R | R | R |
| Ceftazidime | R | R | R | R |
| Floxomef | R | R | S | S |
| Aztreonam | R | R | R | R |
| Trimethoprim-sulfamethoxazole | R | R | R | |
| Ciprofloxacin | S | R | S | S |
| Imipenem | S | S | ||
| Meropenem | S | |||
| Ertapenem | S | |||
IVDU = intravenous drug use; S = susceptible; R = resistant.